Delamanid Access Widened But TB Groups Want More
This article was originally published in PharmAsia News
Executive Summary
Otsuka has agreed a plan with the Global Drug Facility to improve the worldwide distribution of its novel TB drug delamanid, but several access groups are asking for additional action to combat the multidrug-resistant form of the disease.